Holen Sie sich die Stockscreener-App
8.71
1.16%
0.10
Handel nachbörslich:
8.84
0.13
+1.49%
Schlusskurs vom Vortag:
$8.61
Offen:
$8.61
24-Stunden-Volumen:
846.97K
Relative Volume:
0.56
Marktkapitalisierung:
$422.64M
Einnahmen:
$217.11M
Nettoeinkommen (Verlust:
$-651.19M
KGV:
-0.6705
EPS:
-12.99
Netto-Cashflow:
$-387.26M
1W Leistung:
+11.24%
1M Leistung:
-35.81%
6M Leistung:
+24.61%
1J Leistung:
+7.00%
1-Tages-Spanne:
$8.41
$8.855
1-Wochen-Bereich:
$7.63
$8.855
52-Wochen-Spanne:
$5.00
$17.58
Ginkgo Bioworks Holdings Inc Stock (DNA) Company Profile
Firmenname
Ginkgo Bioworks Holdings Inc
Sektor
Branche
Telefon
(877) 442-5362
Adresse
27 DRYDOCK AVENUE, BOSTON
Vergleichen Sie DNA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DNA
Ginkgo Bioworks Holdings Inc
|
8.71 | 521.68M | 217.11M | -651.19M | -387.26M | -12.99 |
|
VRTX
Vertex Pharmaceuticals Inc
|
429.82 | 107.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.32 | 80.03B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.80 | 57.37B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
917.93 | 55.83B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
209.02 | 44.13B | 447.02M | -1.18B | -906.14M | -6.1812 |
Ginkgo Bioworks Holdings Inc Stock (DNA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-05-15 | Herabstufung | BTIG Research | Neutral → Sell |
| 2024-05-10 | Herabstufung | William Blair | Mkt Perform → Underperform |
| 2023-11-14 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2023-11-09 | Herabstufung | BTIG Research | Buy → Neutral |
| 2023-06-02 | Herabstufung | Goldman | Neutral → Sell |
| 2023-05-11 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2022-11-29 | Eingeleitet | Berenberg | Buy |
| 2022-10-04 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-05-18 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-03-02 | Fortgesetzt | Cowen | Outperform |
| 2022-02-23 | Eingeleitet | Goldman | Neutral |
| 2022-02-01 | Eingeleitet | BofA Securities | Neutral |
| 2022-01-28 | Eingeleitet | BofA Securities | Buy |
| 2022-01-07 | Eingeleitet | BTIG Research | Buy |
| 2021-11-29 | Eingeleitet | Jefferies | Buy |
| 2021-10-13 | Eingeleitet | Raymond James | Outperform |
| 2021-10-12 | Eingeleitet | William Blair | Outperform |
| 2021-09-20 | Eingeleitet | HSBC Securities | Buy |
Alle ansehen
Ginkgo Bioworks Holdings Inc Aktie (DNA) Neueste Nachrichten
What analysts say about Ginkgo Bioworks Holdings Inc stockMarket Capitalization Trends & High Return Capital Strategies - earlytimes.in
(DNA) as a Liquidity Pulse for Institutional Tactics - news.stocktradersdaily.com
How Ginkgo Bioworks Holdings Inc. Class stock compares with tech leaders2025 Geopolitical Influence & AI Forecast for Swing Trade Picks - newser.com
How Ginkgo Bioworks Holdings Inc. Class stock benefits from digital adoptionStop Loss & Weekly High Potential Stock Alerts - newser.com
Will Ginkgo Bioworks (DNA) Leverage ARPA-H Partnership to Advance Its Oral Therapeutics Ambitions? - Yahoo Finance
Ginkgo Bioworks: Scaling Science, Not Revenue (NYSE:DNA) - Seeking Alpha
Is Ginkgo Bioworks Holdings Inc. Class stock resilient in recession scenarios - newser.com
Ginkgo Bioworks Holdings Inc. stock daily chart insightsJuly 2025 Breakouts & Long Hold Capital Preservation Plans - newser.com
Can Ginkgo Bioworks Holdings Inc. stock beat market expectations this quarter - newser.com
Will Ginkgo Bioworks Holdings Inc. stock gain from lower inflationWeekly Market Summary & Real-Time Price Movement Reports - newser.com
Is it time to cut losses on Ginkgo Bioworks Holdings Inc.Trade Exit Summary & AI Based Buy and Sell Signals - newser.com
Exit strategy if you’re trapped in Ginkgo Bioworks Holdings Inc.2025 Institutional Moves & Consistent Profit Trade Alerts - newser.com
Can Ginkgo Bioworks Holdings Inc. stock surprise with earnings upsideEarnings Overview Summary & AI Powered Buy/Sell Recommendations - newser.com
Published on: 2025-11-19 04:21:37 - newser.com
Will Ginkgo Bioworks Holdings Inc. Class stock deliver compounding returnsQuarterly Risk Review & Accurate Entry and Exit Point Alerts - newser.com
Ginkgo Bioworks (DNA): Rethinking Valuation After New University Collaboration in ARPA-H MIGHTY Oral Health Initiative - Yahoo Finance
Will Ginkgo Bioworks Holdings Inc. Class stock announce a stock splitQuarterly Trade Review & Reliable Entry Point Alerts - newser.com
Ginkgo Bioworks Partners on Illinois-Led Team to Develop Innovative New Treatments for Oral Health - Finviz
Ginkgo Bioworks Holdings, Inc. Class A Common Stock (NY: DNA - Markets Financial Content
Frontier, Gevo (NASDAQ: GEVO) launch CO₂ rail network for ethanol plants in U.S. - Stock Titan
Is Ginkgo Bioworks Holdings Inc. Class stock a defensive play amid uncertaintyEarnings Trend Report & Verified Short-Term Trading Plans - newser.com
Why Investors Shouldn't Be Surprised By Ginkgo Bioworks Holdings, Inc.'s (NYSE:DNA) 39% Share Price Plunge - simplywall.st
Ginkgo Bioworks Holdings (DNA) Price Target Decreased by 11.11% to 10.88 - Nasdaq
Using Python tools to backtest Ginkgo Bioworks Holdings Inc. strategiesLong Setup & Real-Time Chart Breakout Alerts - newser.com
Finanzdaten der Ginkgo Bioworks Holdings Inc-Aktie (DNA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.53%
1.88%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):